Lamivudine + Buprenorphine = Unknown or no reaction

Effect on Concentration

Lamivudine
No change
Applies within class?
No
Buprenorphine
No change
Applies within class?
No

Pharmacologic Effects

Lamivudine
Effect
N/A
Applies within class?
No
Buprenorphine
Effect
N/A
Applies within class?
No

Interaction History

N/A

Last Updated 24-Jul-2018

Summary

Sources

Lamivudine versus Buprenorphine ^

Study Design

We report the results of a study designed to examine the interaction between buprenorphine and the nucleos(t)ide reverse transcriptase inhibitors (NRTI) didanosine (ddI), lamivudine (3TC), and tenofovir (TDF). Opioid-dependent, buprenorphine/naloxone-maintained, HIV-negative volunteers (n = 27) participated in two 24-hour sessions to determine (1) pharmacokinetics of buprenorphine alone and (2) pharmacokinetics of both buprenorphine and either ddI, 3TC, or TDF.

Study Results

Among buprenorphine/naloxone-maintained study participants, no significant changes in buprenorphine pharmacokinetics were observed following ddI, 3TC, or TDF administration. Buprenorphine had no significant effect on NRTI concentrations.

Study Conclusions

Concomitant use of buprenorphine with 3TC results in neither a significant pharmacokinetic nor pharmacodynamic interaction. As such these drugs can be coadministered without dose adjustment for opioid addicted patients using lamivudine.

References

Baker J, Rainev PM, Moody DE, Morse GD, Ma Q, McCance-Catz EE. Interactions between buprenorphine and antivirals: nucleos(t)ide reverse transcriptase inhibitors (nrti) didanosine, lamivudine, and tenofovir. American Journal On Addictions. 2010; 1: 17-29.